Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises the management in connection with the acquisition of Erlandsson Bygg AB
Mandate

Vinge advises the management in connection with the acquisition of Erlandsson Bygg AB

July 10, 2019 M&A

Vinge has advised the management of Erlandsson Bygg AB in connection with their acquisition of the remaining 60 per cent of the company’s shares from Erlandsson Bolagen i Kungsbacka AB.

The new company has 460 employees, excluding subsidiaries, and has a budgeted turnover of SEK 2.2 billion. It operates in western Sweden; from Strömstad to Halmstad, towards Småland and up to Värmland and Örebro. The business remains broad and focuses on, among other things, contracting, construction and damage services as well as project development. The head office of the new company is in Mölndal, Gothenburg. 

Vinge’s team has consisted of Magnus Pauli and Edin Agic. 
 

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

 SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026